» Articles » PMID: 21481792

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2011 Apr 13
PMID 21481792
Citations 343
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-infiltrating myeloid cells convey proangiogenic programs that counteract the efficacy of antiangiogenic therapy. Here, we show that blocking angiopoietin-2 (ANG2), a TIE2 ligand and angiogenic factor expressed by activated endothelial cells (ECs), regresses the tumor vasculature and inhibits progression of late-stage, metastatic MMTV-PyMT mammary carcinomas and RIP1-Tag2 pancreatic insulinomas. ANG2 blockade did not inhibit recruitment of MRC1(+) TIE2-expressing macrophages (TEMs) but impeded their upregulation of Tie2, association with blood vessels, and ability to restore angiogenesis in tumors. Conditional Tie2 gene knockdown in TEMs was sufficient to decrease tumor angiogenesis. Our findings support a model wherein the ANG2-TIE2 axis mediates cell-to-cell interactions between TEMs and ECs that are important for tumor angiogenesis and can be targeted to induce effective antitumor responses.

Citing Articles

Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.

Toghraie F, Bayat M, Hosseini M, Ramezani A Cell Oncol (Dordr). 2025; .

PMID: 39998754 DOI: 10.1007/s13402-025-01051-y.


Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.


Prognostic value of circulatory growth factors to predict responsiveness to chemotherapy and remission status of patients with acute myeloid leukemia.

Bani-Ahmad M, Ghanem D Arch Med Sci. 2025; 20(6):1887-1893.

PMID: 39967929 PMC: 11831328. DOI: 10.5114/aoms/185617.


The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.

Gupta V, Roby K, Pathak H, Godwin A, Gunewardena S, Khabele D BMC Cancer. 2025; 25(1):233.

PMID: 39930466 PMC: 11812249. DOI: 10.1186/s12885-025-13640-z.


Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy.

Li H, Gan R, Liu J, Xu D, Zhang Q, Tian H Mater Today Bio. 2025; 30:101455.

PMID: 39866777 PMC: 11762577. DOI: 10.1016/j.mtbio.2025.101455.